Nine Chapters Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Nine Chapters Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-16,600	Closed	-$134K	–	1108
2015 Q2	$134K	Buy	16,600 +11,643	+235%	+$85.5K	0.01%	848
2015 Q1	$33K	Sell	4,957 -1,214	-20%	-$8.29K	﹤0.01%	935
2014 Q4	$39K	Buy	+6,171	New	+$49.7K	﹤0.01%	897
2014 Q2	–	Sell	-2,843	Closed	-$34K	–	1044
2014 Q1	$34K	Buy	2,843 +300	+12%	+$3.83K	﹤0.01%	785
2013 Q4	$32K	Buy	2,543 +572	+29%	+$9.1K	﹤0.01%	767
2013 Q3	$33K	Buy	+1,971	New	+$33.1K	﹤0.01%	722

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nine Chapters Capital Management's LXRX Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2015, closing a stake of 16,600 shares — an estimated $134K sold.

Nine Chapters Capital Management first reported a position in LXRX in Q3 2013 and held it in 6 quarters. The position peaked at $134K in Q2 2015. 105 funds tracked by Wall St. Rank hold LXRX as of Q3 2015.

Nine Chapters Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
Nine Chapters Capital Management sold 16,600 Lexicon Pharmaceuticals shares in Q3 2015, an estimated $134K.
Nine Chapters Capital Management first reported a position in Lexicon Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Nine Chapters Capital Management's Lexicon Pharmaceuticals position peaked at $134K in Q2 2015.
105 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.